Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics Inc is biotechnology company focused on the development of products for inflammation, inborn errors of metabolism, and other diseases, related to endogenously generated toxic and pro-inflammatory chemical species known as aldehydes.
IPO Date: April 28, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $297.68M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.20 | 3.30%
Avg Daily Range (30 D): $0.13 | 3.36%
Avg Daily Range (90 D): $0.13 | 3.96%
Institutional Daily Volume
Avg Daily Volume: .49M
Avg Daily Volume (30 D): 1.04M
Avg Daily Volume (90 D): 1.45M
Trade Size
Avg Trade Size (Sh.): 139
Avg Trade Size (Sh.) (30 D): 120
Avg Trade Size (Sh.) (90 D): 150
Institutional Trades
Total Inst.Trades: 430
Avg Inst. Trade: $1.73M
Avg Inst. Trade (30 D): $1.44M
Avg Inst. Trade (90 D): $1.43M
Avg Inst. Trade Volume: .23M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.92M
Avg Closing Trade (30 D): $2.09M
Avg Closing Trade (90 D): $2.09M
Avg Closing Volume: 255.05K
   
News
May 15, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating Organ...
Source: N/A
May 3, 2025 @ 11:18 AM
ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:...
Source: N/A
Apr 29, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating TechT...
Source: N/A
Apr 27, 2025 @ 12:20 PM
ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NAS...
Source: N/A
Apr 25, 2025 @ 4:57 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-.17 $-.25
Diluted EPS $-.17 $-.25
Revenue $ $ $
Gross Profit $ $ $
Net Income / Loss $ $ -9.93M $ -15.11M
Operating Income / Loss $ $ -10.43M $ -16.14M
Cost of Revenue $ $ $
Net Cash Flow $ $ -4.18M $ -2.91M
PE Ratio